Clinical Study

A Phase 3, Multicenter, Randomized, Efficacy Assessor-Blinded Study Of Risankizumab Compared To Ustekinumab For The Treatment Of Adult Subjects With Moderate To Severe Crohn's Disease Who Have Failed Anti-Tnf Therapy

Posted Date: Sep 21, 2021

  • Investigator: Loren Brook
  • Specialties:
  • Type of Study: Drug

This study will compare the efficacy and safety of risankizumab versus ustekinumab for the treatment of adult subjects with moderate to severe Crohn's disease (CD) who have failed anti-TNF therapy.


Age 18-80. Diagnosis Of Crohn's Disease For At Least 3 Months Prior To Screening. Willing And Able To Comply With Procedures Required In The Protocol.


Crohn's Disease, Crohn's

For More Information:

Missy Randolph